A deficiency in transforming growth factor beta 1 (TGFb1) causes a lethal inflammatory disease in mice 1, 2 that is eliminated in the absence of T cells but not B cells. 3 The T-cell-dependent inflammatory disease is not pathogen mediated because in TGFb1-deficient mice there is no evidence of bacteria in inflamed tissues, no antibodies to bacteria are found in serum, and no significant bacterial pathogens are detected when samples of inflamed tissues are cultured in pediatric broth. 1 In addition, germ-free Tgfb1 À/À mice (no enteric bacteria in the gut) develop the same inflammatory disease. 4 Consequently, TGFb1 plays an intrinsic role in preventing T-cell activation and activation-induced cell death. [5] [6] [7] We have previously shown that Tgfb1 À/À T cells are activated in vivo due to a lowered threshold of activation resulting from increased [Ca 2 þ ] i levels. 8 Unlike TGFb1 function in T reg cells which is SMAD3 dependent, 9,10 Ca 2 þ /Calcineurin-mediated TGFb1 function in T cells is SMAD3 independent since Smad3 À/À mice do not have this autoimmune disease. 5, [11] [12] [13] Consequently, TGFb1 plays immune regulatory roles in different T cells through different signaling mechanisms, thereby enhancing the potential for fine-tuning the tolerance and response arms of the adaptive immune system. What is as yet unclear is whether the activation of TGFb1-deficient T cells requires self-antigen (self-Ag) recognition, or whether it occurs spontaneously in the absence of any antigenic stimulation.
To test this we have combined Tgfb1 À/À and Tgfb1 À/À Rag1 À/À mice with TCR transgenic mice expressing the OVA-specific TCR DO11. 10 . CD4
þ T cells in DO11.10 mice are known to become activated only when the cognate peptide (a peptide derived from OVA) is presented by MHC II on an I-A d background. Here, we show that complete elimination of self-reactive TCR-bearing T cells is sufficient to rescue Tgfb1 À/À mice from their lethal autoimmune phenotype and to eliminate the hyper-responsiveness of TGFb1-deficient T cells. Consequently, TGFb1 is essential for preventing inappropriate activation of self-reactive T cells.
Materials and methods

Mice
Tgfb1
þ /À mice (BALB/c, N7) were kindly provided by James D Gorham (Dartmouth Medical School). DO11.10 mice were kindly provided by J Gabriel Michael (University of Cincinnati Medical School) and were genetically combined with Rag1 À/À mice in our specific pathogen-free animal facility at the University of Cincinnati Medical Center. DO11.10 Rag1 À/À mice were in turn combined with Tgfb1 þ /À mice to generate Tgfb1 À/À DO11.10 and Tgfb1
À/À DO11.10 Rag1 À/À mice. All mice were used at the ages described in the text and figure legends. All the mice were housed and handled as per approved IACUC protocols at the University of Cincinnati.
Reagents
All media and reagents for cell culture studies were purchased from either Life Technologies (GIBCOBRL) (Rockville, MD, USA) or Sigma (St Louis, MO, USA). Paraformaldehyde was purchased from Electron Microscopy Sciences (Washington, PA, USA). Thymidine, [Methyl- 3 H]-(specific activity 6.7 Ci/mmol) was purchased from NENt Life Science Products Inc. (Boston, MA, USA). Tissue culture plates were purchased from Becton Dickinson (Franklin Lakes, NJ, USA). PMA (10 mM) and Ionomycin (100 mM) stocks were prepared in DMSO, aliquoted and stored at À801C.
Antibodies
Purified anti-mouse CDe, anti-mouse CD28, antimouse CD16/CD32 (FcgIII/II receptor), anti-mouse interleukin-2 (IL-2) and anti-mouse interferon gamma (IFNg) antibodies, FITC-anti-mouse CD3e, FITC-CD69, FITC-or APC-CD44, FITC-or PerCP-antimouse CD4 (L3T4), APC-CD62L, R-PE-conjugated anti-mouse antibodies to CD25, CD44, CD49d, CD62L and CD69, and fluorochrome-conjugated isotype control antibodies were purchased from either BD Pharmingen (San Diego, CA, USA) or eBioscience (San Diego, CA, USA). R-PE-anti-mouse CD11a (LFA-1) was purchased from BioDesign (Saco, ME, USA). FITC-, PE-or APC-KJ1-26 (clonotypic anti-TCR Ab against DO11.10 TCR) was purchased from CALTAG (Burlingame, CA, USA). FOXP3 staining kit (clone FJK-16s) was purchased from eBioscience (San Diego, CA, USA).
PCR Genotyping
The genotype of newborn pups from heterozygous matings was determined by PCR amplification of tail DNA and size fractionation on agarose gels. 14 Genotyping of DO11.10 mice and TCR expression were also determined by PCR amplification of tail DNA and flow cytometry of splenic T cells.
Splenocyte proliferation and phenotype analysis
Single-cell suspensions were prepared, enumerated and assayed for their mitogenic response using a [ 3 H]thymidine incorporation assay after 2 days of in vitro culture as described. 7 Culture supernatants were collected and frozen until cytokines were analyzed by sandwich ELISA as described earlier. 7 Phenotype analysis of splenocytes was determined by four-color flow cytometry using BD-LSR flow cytometer with the appropriate fluorochromeconjugated antibodies (BD Pharmingen, San Diego, CA, USA) as described. 7 Cells were stained for surface markers, as described previously. 7 For detecting intracellular FOXP3 expression, the surface-stained cells were fixed and permeabilized using the Fix/Perm buffer overnight at 41C and stained for FOXP3. Cytokines were assayed in culture supernatants, as described previously. 7 Inflammation score Animals were euthanized following institutional guidelines and tissues were fixed in 10% neutralbuffered formalin. Tissues were dehydrated through a gradient of alcohol and xylene, embedded in paraffin, and 5 mm sections were cut and H&E stained. An inflammation score was assigned to each tissue depending on the severity of the inflammatory cell infiltrate: 0 (no inflammation), 0.5 (very mild), 1.0 (mild), 2 (moderate), 3 (severe) and 4 (very severe). 3, 7 Very mild: the inflammatory cells are very infrequent and usually involve less than 10 cells. Mild: inflammatory component is composed of less than 100 cells. The inflammation is confined to a few areas in the tissues. Moderate: inflammation involves multiple areas in the tissue or is a large area composed of more than 100 inflammatory cells but less than 1000 cells. There may be associated tissue damage near the inflammatory component. Severe: inflammatory cells TGFb1 prevents autoimmune T-cell activationcomprise large multifocal areas of the tissue and usually involves at least 20% of the tissue. There are greater than 1000 cells involved. There is clear alteration of the adjacent tissues either due to compression from the inflammatory component or necrosis of the adjacent tissue. Very severe: similar to severe only nearly all areas of the tissue are affected. There is alteration of the normal parenchyma appearance. Data for the most commonly affected organs are shown in the figures.
Statistical analysis
Survival rates were calculated using Kaplan-Meier method, frequencies of affected tissues were calculated using w 2 -test, and the mean body weights were compared using Student's t-test. Figure 1a ), but, as is also the case for Tgfb1 À/À mice, they are smaller than their wild-type (WT) littermates and exhibit a wasting syndrome (Po0.01 at most age groups, Student's t-test; Figure  1b ). This observation is consistent with our previous studies which suggested that the wasting syndrome is neither due to inflammation nor lymphocytes although inflammatory stress accelerates wasting in Tgfb1 À/À mice. 1, 14, 15 As failure to thrive and development of a wasting syndrome may occur due to abnormalities in the gastrointestinal tract, we investigated gastrointestinal tract lesions and found a moderate to severe loss of parietal cells in the stomach in 36% of mice, colon/cecal inflammation in 18%, and hyperplasia in colon/cecum in 9% (n ¼ 22 Tgfb1 À/À DO11.10 mice). The loss of parietal cells in these mice could result from a humoral autoimmune response causing production of autoantibodies to parietal cells and development of autoimmune gastritis 16 since Tgfb1 À/À B cells are also hyper-responsive in these mice (Bommireddy et al 3 data not shown). These findings are consistent with our earlier observations suggesting that the wasting syndrome in Tgfb1 À/À mice is T-cell independent. 15, 17 Further, neutrophils and macrophages are the major contributors to the mild inflammation observed in Tgfb1 À/À Rag-deficient mice. 14, 17 Evaluation of inflammatory lesions shows that among the 22 Tgfb1 À/À DO11.10 mice that we have analyzed thus far, most Tgfb1 À/À DO11.10 mice either have no inflammation in all tissues examined (14%) or have inflammation in only 1-4 tissues (77%), which is in contrast to the immunocompetent Tgfb1 À/À BALB/c (Tgfb1 À/À TCR nontransgenic) cohort where 96% of 25 mice have inflammation in Z4 organs and no mice are devoid of inflammation ( Figure 1c) . 3, 7 The inflammation index, defined as the sum of the severity (0-4) of inflammation from 25-30 tissues divided by the number of tissues evaluated (Figure 1d ), was dramatically reduced in Tgfb1 À/À DO11.10 mice relative to Tgfb1 À/À animals (0.11 vs 0.49, ie, 4.5-fold reduction). 7 Further histological analysis of individual tissues reveals that 59% of mice have either mild or no inflammation in the tissues examined, 32% of the mice have moderate to severe inflammation in lungs and pancreas, and only 9% have moderate inflammation in all other tissues examined ( Figure 1d ). This is in contrast to Tgfb1 À/À mice which show moderate to severe inflammation in all tissues examined by 3 weeks of age. 1 Representative tissue sections show that whereas no significant inflammation is seen in the liver of Tgfb1 
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TGFb1 prevents autoimmune T-cell activationmice is due to the presence of TCR nontransgenic T cells and hybrid TCR on DO11.10 T cells, we have generated Tgfb1 À/À DO11.10 Rag1 À/À mice which should harbor no hybrid TCR. Four mice were analyzed for inflammation and T-cell activation. As expected, these mice did not develop significant inflammation in any organ (Figure 2a) . Only minimal inflammation, primarily due to neutrophil and macrophage infiltration, was present in the cecum (1 of 4), colon (1 of 4), liver (1 of 4) and lungs (2 of 4) of these mice. This is also consistent with our previous observation that neutrophils and macrophages do contribute to mild inflammation and inflammatory bowel disease-mediated colon cancer in Tgfb1 À/À Rag2 À/À mice, 14 a disease that is not autoimmune in nature because it is completely eliminated by rendering the mice germ-free. 15 Consistent with a low level of inflammation in Tgfb1
À/À mice, these mice are smaller than their Tgfb1 þ / þ littermate controls (Figure 1b) , as also previously reported in Tgfb1
14,17
Flow cytometry of splenocytes and thymocytes revealed that thymocyte development in Tgfb1 We have previously shown that thymic T-cell development is normal until 1 week after birth in Tgfb1 À/À mice; 8 but as these mice start developing inflammatory lesions in peripheral tissues, the thymus becomes smaller and is often invisible by the time they are moribund at about 3 weeks of age. This is due to cortical depletion as evidenced by a severe reduction in CD4 þ CD8 þ thymocytes and a consequent increase in the proportion of CD4 þ CD8 À thymocytes. 8, 19 We have previously suggested that the impairment in thymocyte development in Tgfb1 À/À mice is affected by the inflammatory environment 8 and not due to the absence of TGFb1 alone. To test this idea further we analyzed the thymocyte profile in 4 to 8-week-old Tgfb1 À/À DO11.10 mice and their control littermate DO11.10 mice. Indeed, thymocyte development is nearly normal in these mice regardless of the presence or absence of TGFb1 (Figure 3a , right and middle panels). This is in contrast to a day 21 Tgfb1 À/À mouse which exhibits a severe decrease in doublepositive thymocytes and a marked increase in CD4 þ CD8 À cells in the thymus (Figure 3a , left panel). This demonstrates that elimination of selfAg recognition, which reduces inflammation in Tgfb1 À/À DO11.10 mice (Figure 1 (Figure 3b , left quadrants). To our surprise, we observed that the transgenic T-cell population (KJ1-26 þ ) also exhibits significant activation in Tgfb1 À/À DO11.10 mice, as evidenced by an increase in the percentage of activated KJ1-26 þ CD4 þ T cells (Figure 3b) . Further, the mean fluorescence intensity (MFI) of surface markers, such as CD11a, CD44 and CD49d, is increased, and that of CD62L, is reduced on Tgfb1 À/À DO11.10 T cells (data not shown; Figure  5c ), indicating their activation.
We have recently reported that in the periphery Tgfb1 À/À T cells, but not B cells, exhibit a split anergic response to mitogenic stimulation as evidenced by decreased IL-2, IL-4 and IL-10 production and diminished [Ca 2 þ ] i flux in response to anti-CD3 stimulation. 3, 7 This split anergic response to receptor-mediated stimulation is mainly due to prior activation in vivo as evidenced by CD3 and CD8 downmodulation, increased expression of CD11a (LFA-1) and IFNg, elevated cytosolic [Ca 2 þ ] i levels and increased cell size. 7 Also, stimulation of these cells with receptor-independent mitogenic stimulation such as PMA plus ionomycin rescues them from such ex vivo hyporesponsiveness. 7 However, since inflammation develops very early in the life of these mice, it was difficult to conclude whether the hyporesponsiveness of T cells was due to the absence of TGFb1, due to the highly inflamed environment, or due to their prior activation in vivo. Hence, we determined T-cell responses in the 
(d). (e) Tgfb1
À/À CD4 þ T cells are activated in vivo. Splenocytes from three 2-to 3-week-old Tgfb1 À/À and littermate control mice (d20 shown here) were prepared and stained for surface expression of CD4, CD44 and CD62L. CD44 and CD62L expression was analyzed on CD4 þ -gated splenocytes as described in Materials and methods.
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À/À DO11.10 mice.
Mature Splenic T Cells Exhibit Split Anergic Response to Ex Vivo Stimulation
Consistent with the increase in activation markers on Tgfb1 À/À DO11.10 T cells (Figure 3b ), the Tgfb1 À/À DO11.10 splenocytes, upon stimulation with mitogens, produce more IFNg than the Tgfb1
DO11.10 cells (Figure 4a , upper panels). IL-2 production in these cultures, however, is lower than in control cultures stimulated with anti-CD3 or Con A. Stimulation with PMA plus ionomycin, which causes TCR-independent activation by acting directly on cytosolic signaling targets, increases the TGFb1 prevents autoimmune T-cell activation R Bommireddy et al production of IL-2 by Tgfb1 À/À DO11.10 splenocytes (Figure 4a, lower panels) . Such split anergy in T-cell responses to mitogens (decreased IL-2, but increased IFNg production) in Tgfb1 À/À DO11.10 mice is likely due to the prior activation of T cells in vivo as we have shown previously with T cells from Tgfb1 À/À mice. 7 Consistently, the T cells' proliferative response to mitogenic stimulation is also decreased in Tgfb1 À/À DO11.10 mice compared with cells from control mice (Figure 4b) Table. TCR downmodulation is consistent in all the KO mice tested thus far. Data shown are from a mouse that had moderate inflammation only in the lung and pancreas. Data represent three to six experiments. Ntg, nontransgenic. mice (Figure 4c) . Thus, Tgfb1 À/À T cells exhibit evidence of in vivo activation even in animals that have minimal to no inflammation, suggesting that the observed T-cell phenotype does not occur as a consequence of inflammation.
These data might suggest that DO11.10-positive T cells undergo activation and become effector/effector memory cells without any antigenic stimulation. One possible explanation could be that activation of transgenic T cells results from bystander activation from the few neighboring, nontransgenic (KJ1-26
þ ) cells which would recognize self-Ag and undergo spontaneous activation. However, the activation of Tgfb1 À/À DO11.10 T cells was observed even in animals that did not have any detectable inflammatory lesions, suggesting that bystander activation is less likely to be the reason for the activation of these T cells. Another possible explanation is that hybrid TCR (transgenic TCRb and endogenous TCRa) are present which can recognize self-Ag.
Presence of Hybrid TCR in Tgfb1
À/À DO11.10 T Cells
Activation of transgenic T cells in the absence of a cognate antigen (Figure 3b ) suggests a possibility that these cells may harbor a hybrid TCR which could recognize self-Ag and undergo activation. This is possible because of endogenous TCRa chain productive rearrangement in a RAG-sufficient background such that the rearranged TCRa can then dimerize with the transgenic TCRb chain. Indeed, the TCRva2 chain that is known to be found on a small fraction of DO11.10 T cells 20 is expressed on DO11.10 CD4 þ T cells and is downregulated on Tgfb1 À/À CD4 þ T cells (Figure 5a , B2-fold decrease in MFI). Downregulation of TCRva2 in Tgfb1 À/À T cells was also observed on KJ1-26 þ T cells (hybrid TCR-expressing T cells; upper right quadrants in Figure 5b ) albeit to a lesser extent. This suggests that Tgfb1 À/À DO11.10 T cells might utilize hybrid TCR to recognize self-Ag and undergo activation. Comparing activation markers and adhesion molecules on DO11.10-positive and -negative T cells within the same splenic population revealed that cells that can recognize self-Ag (DO11.10-negative; right panels in Figure 5c ) have higher levels of CD11a, CD44, CD49d and CD69 than do the DO11.10-positive T cells (left panels in Figure 5c ) that may not recognize self-Ag. Upregulation of these surface markers is further enhanced by the deficiency of TGFb1 suggesting increased self-Ag recognition in the absence of TGFb1 (Figure 5c 
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is not altered on Tgfb1 À/À DO11.10 splenocytes (data not shown). These data demonstrate the presence of hybrid TCR in Tgfb1 À/À DO11.10 T cells allowing them to recognize self-Ag and undergo activation.
Discussion
We and others have reported that Tgfb1 À/À mice develop multiorgan inflammation, which is caused at least in part by in vivo T-cell activation. 1, 2, 7 The mechanisms of T-cell activation and inflammation remain unclear. In this article we asked whether a TGFb1 deficiency leads to enhanced self-Ag recognition by T cells, thus causing their inappropriate activation and T-cell-mediated inflammation. To address this question we generated Tgfb1 À/À DO11.10 mice that carry primarily transgenic T cells as well as some endogenous T cells, and Tgfb1
À/À DO11.10 Rag1 À/À mice that carry only transgenic T cells. As the antigenic ligand for these T cells is not present in these mice, we did not expect to see spontaneous T-cell activation. Furthermore, we expected these mice to have less inflammation and survive longer, thus permitting future studies on the effect of TGFb1 deficiency on T-cell activation in the absence of inflammation.
Reducing Endogenous T Cells Reduces Inflammation in Tgfb1
À/À Mice, Whereas Eliminating Endogenous T Cells Completely Rescues Them from Autoimmune Inflammation.
In this paper we demonstrate that Tgfb1 À/À DO11.10 mice live longer and develop a much milder inflammation in fewer organs than occurs in Tgfb1 À/À nontransgenic animals. The reduced inflammation in Tgfb1 À/À DO11.10 mice does not likely result from reduced T-cell numbers as the elimination of either CD4 þ or CD8 þ T cells neither lessens the severity of inflammation nor increases survival of Tgfb1 À/À mice. 3 As Tgfb1 À/À DO11.10 mice still have some endogenous T cells, we generated Tgfb1 À/À DO11.10 Rag1 À/À mice to eliminate all nontransgenic T cells. These mice live even longer (mean of 8 vs 3 weeks) and do not exhibit significant inflammation in the organs that are usually affected by autoimmunity in Tgfb1 À/À mice. Thus, endogenous (self-reactive) T cells play a critical role in the development of multiorgan inflammation in Tgfb1 À/À mice.
TGFb1 Deficiency does not Broadly Impair Thymic Development
In Tgfb1 À/À mice that are less than a week old and have no significant inflammation, 8 thymocyte development is nearly normal. The thymus becomes smaller, however, as these animals begin to develop inflammatory lesions. At that stage we find cortical depletion, depletion of double-positive thymocytes and an increase in the CD4 þ population. This suggested to us that the cortical depletion observed in Tgfb1 À/À mice is probably secondary to inflammation, rather than owing to a direct effect of TGFb1 on thymocytes in the cortex. Improved survival and delayed inflammation in Tgfb1 À/À DO11.10 mice allowed us to examine this issue further. Histological and flow cytometry analyses of thymus suggested that there was neither cortical depletion nor a shift in thymocyte profiles before the onset of wasting in Tgfb1 À/À DO11.10 mice. Normal thymocyte profiles are seen even after 2 months of age in Tgfb1 À/À DO11.10 mice. It is noteworthy that thymocyte development is similar to littermate controls in Tgfb1 À/À DO11.10 Rag1 À/À mice. Thus, we propose that it is the inflammation and not the lack of TGFb1 that causes the thymic cortical depletion in Tgfb1 À/À mice and that TGFb1 probably does not play a direct role in thymic development.
Elimination of Endogenous TCR in Tgfb1
À/À Mice Prevents Activation of Transgenic T Cells
As is the case for Tgfb1 À/À T cells in nontransgenic mice, 7 Tgfb1 À/À DO11.10 CD4 þ T cells exhibit a split anergic phenotype as demonstrated by increased IFN-g production and TCR downmodulation, and reduced proliferation and IL-2 production in response to ex vivo receptor-mediated mitogenic stimulation. These data suggest that Tgfb1 À/À DO11.10 T cells become activated in vivo in response to self-Ag presentation and display a split anergic phenotype when stimulated ex vivo with Con A or anti-CD3.
Interestingly, activation of DO11.10 transgenic T cells occurs in Tgfb1 À/À mice without any cognate peptide-Ag in vivo. This phenomenon could be due either to the presence of bystander nontransgenic T cells that recognize self-Ag and undergo activation and activate KJ1-26 þ T cells, to the presence of hybrid TCR which can recognize self-Ag, or to both. Indeed, some transgenic (KJ1-26 þ CD4 þ ) T cells also express endogenous TCRva2, suggesting that hybrid TCR expression on KJ1-26 þ T cells could be primarily responsible for their activation through the recognition of self-Ag. To test this further, we generated Tgfb1 À/À DO11.10 Rag1 À/À mice that have no nontransgenic T cells and no hybrid TCR-bearing transgenic T cells. In these mice, splenic T cells do not exhibit any evidence of activation. These data clearly indicate that Tgfb1 À/À T cells undergo activation due to their reactivity towards self-Ag, and that elimination of self-reactive TCR-bearing T cells eliminates T-cell activation and inflammation in Tgfb1 À/À mice. Recent studies have suggested that TGFb1 is required for peripheral maintenance of T reg cells, as the percentage of CD4 þ CD25 þ T cells are decreased þ T reg -cell generation is self-Ag dependent and TGFb1 might modulate their generation indirectly. These findings are discussed further in a separate report (manuscript submitted).
Non-T-Cell Effects of TGFb1 Deficiency
Despite a relatively modest systemic inflammation in Tgfb1 À/À DO11.10 mice, these mice still exhibit a wasting syndrome similar to that of lymphocytedeficient Rag1 À/À TCR nontransgenic Tgfb1 À/À mice, suggesting that TGFb1 may have additional roles that contribute to the thriving of these mice. The wasting syndrome is independent of lymphocyte activation because Tgfb1 À/À Rag2 À/À and Tgfb1 . Tgfb1 À/À mice usually die within 3-4 weeks after birth, and this depends on the genetic background. Tgfb1 À/À mice on a BALB/c background develop disease earlier and die earlier than when on other backgrounds. Tgfb1 À/À mice on SCID (primarily C3H) or RAG KO (primarily 129) backgrounds live longer, but eventually die (2-6 months) of either wasting (both backgrounds) or colon cancer (primarily 129 background only).
In summary, naïve T cells interact with self-MHC for long-term survival in the periphery. The signal strength generated during such interactions needs to be maintained at such a level that the T cells do not undergo inappropriate activation. TGFb1 plays a critical role in regulating the threshold level of activation to induce tolerance instead of activation, thus maintaining immune homeostasis and preventing autoimmunity. Our data indicate that Tgfb1 À/À T cells become activated through self-Ag recognition thus causing autoimmune inflammation.
